Intuitive Surgical Raises 2026 Outlook as Robotic Surgery Expands Into General Surgery and Gynecology

Intuitive Surgical reported 16% worldwide da Vinci procedure growth in the first quarter of 2026 and lifted its full-year guidance to 13.5–15.5%, driven by expansion in general surgery and a 31% rise in after-hours procedures in the U.S., according to MedTech Dive. The quarter came with revenue of $2.77 billion and shares climbed nearly 8% on the news. For founders building surgical devices or adjacent enabling technology, the Q1 numbers carry a more specific signal than general market momentum.

What the Q1 Procedure Numbers Tell Founders About Where the Market Is Going

Intuitive’s Q1 breakdown shows 14% U.S. procedure growth and 19% international, per MedTech Dive. The U.S. driver was general surgery and gynecology, not urology, combined with a 31% rise in after-hours utilization as hospitals worked to extract more throughput from their existing da Vinci installations. International growth was partly offset by competitive pricing pressure in China and persistently below-historical performance in Japan.

The specialty expansion matters for founders because it changes who the clinical champion is at the accounts now converting to robotics. Urology established the da Vinci’s initial commercial footprint in the U.S. General surgery and gynecology champions carry different evidence requirements, different procedural cadence, and different relationships with hospital administration. The accounts coming online in 2026 are not the same programs that adopted early. Founders building for any of these specialties are dealing with a different procurement environment than the one that existed three years ago, and that changes what your first reference site needs to look like and what evidence it takes to move the next ten.

The raised guidance also implies Intuitive expects this conversion rate to continue. That creates a specific window for founders building complementary devices and tools at exactly the moment when the installed base is expanding fastest. Whether that window is an advantage for you depends on whether your evidence plan is calibrated to this cohort of new accounts rather than to the early-adopter programs that have been running for a decade.

Medtronic Closes $585 Million Acquisition of CathWorks

Medtronic closed its $585 million acquisition of CathWorks on April 20, 2026, per MedTech Dive. CathWorks makes the FFRangio system, which uses AI and computational modeling to derive fractional flow reserve values from standard coronary angiograms, eliminating the need for a pressure wire or adenosine administration. Medtronic had been co-promoting the system since 2022 before the deal, announced in February, closed this month.

The deal confirms a pattern worth noting for founders building AI-enabled diagnostic tools in interventional specialties. By the time Medtronic closed, CathWorks was not a startup with a compelling technology thesis. It was a commercial asset with an established reimbursement position, peer-reviewed clinical data, and an integrated workflow position at cath labs in multiple markets. The acquisition premium was paid for that finish, not for the potential. For founders in AI diagnostics categories, the CathWorks outcome is a more instructive data point about what acquirers are actually paying for than any earlier-stage deal.

Stereotaxis Announces Acquisition of Robocath for Endovascular Robotics

Stereotaxis announced in April 2026 that it would acquire Robocath for up to $45 million, per MedTech Dive. The deal combines Stereotaxis’s magnetic robotic navigation technology with Robocath’s mechanically actuated robotic catheter platform for endovascular surgery. CEO David Fischel described the combination as uniting two complementary navigation modalities. Stereotaxis had received FDA approval for its Magic ablation catheter in January 2026, entering the disposables market for its robotic EP systems for the first time.

For founders building in endovascular robotics or catheter navigation, the acquisition reflects consolidation of technical approaches in a market that has developed largely in parallel across magnetic and mechanical modalities. It also signals that Stereotaxis is moving into a more aggressive commercial posture as it builds out a complete platform rather than a navigation-only story.

Medtronic Leads $100 Million Investment in Pulnovo Medical

Medtronic led a $100 million investment in Pulnovo Medical on April 21, 2026, alongside a commercial agreement, per MedTech Dive. Pulnovo is developing pulsed field ablation technology for cardiac arrhythmia treatment, entering a market where Boston Scientific’s Farapulse system has established the current cleared standard. The investment follows Medtronic’s CathWorks close and reflects continued portfolio expansion in cardiac electrophysiology and structural heart.

The PFA market has moved from a single cleared system to a multi-vendor competitive environment faster than most procedural device categories do. For founders building tools adjacent to EP labs, including mapping, imaging, or workflow software, the strategic relationships available in that setting are changing, and the companies that established early positions with the Farapulse accounts may find those relationships revalued as new platforms arrive.